OGN News and Press, Organon & Co. From 02/15/23

Organon ( NYSE: OGN ) is scheduled to announce Q4 earnings results on Thursday, February 16th, before market open. The consensus EPS Estimate is $0.91 (-33.6% Y/Y) and the consensus Revenue Estimate is $1.5B (-6.3% Y/Y). Over the last 1 year, OGN has beaten EPS estimates 1...

Summary Viatris and Organon are what can currently be described as "deep value plays" in the pharmaceutical sector. They face largely similar challenges, but on closer inspection are quite different companies. While I have already reported on Viatris' ever-changing portfolio, in this ar...

Summary Organon has a solid portfolio driven by steady established brands and fast-growing Women's Health. Management is exercising balance sheet discipline by paying down debt all while maintaining a very well covered dividend. Investors could potentially see strong total returns f...

Summary Organon is a business I own - but only due to being awarded a significant number of shares, some of which I actually sold early on. I kept a stake. In this article, I'm going to follow a subscriber request and dive into what Organon might do for its shareholders, if you did not ...

Organon (NYSE: OGN), a global women’s healthcare company will release its fourth quarter and full year 2022 financial results on February 16, 2023, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EST. Interested parties may access the live call via web...

Organon & Co. (OGN) 41st Annual J.P. Morgan Healthcare Conference January 10, 2023, 10:30 AM ET Company Participants Kevin Ali - CEO Matt Walsh - CFO Conference Call Participants Chris Schott - JPMorgan Presentation Chris Schott Good mor...

Agreement reinforces Organon’s continued focus on pursuing new solutions in high-need areas of women’s health Organon (NYSE: OGN), a global women’s healthcare company, today announced a strategic investment in Claria Medical, Inc. a privately-held company developing...

Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the 41 st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10th, 2023 at 7:30 a.m. PT. Investors, analys...

Summary We've witnessed such a quick and sharp correction in the stock market that the S&P 500 nearly moved from bear-market to bull-market in a matter of weeks. Nonetheless, there are still plenty of signs suggesting that this rapid move isn't going to last much longer, therefore w...

DARE -PDM1 Utilizes Proprietary Hydrogel Technology for Vaginal Delivery of Diclofenac, a Nonsteroidal Anti-Inflammatory; Phase 1 Study Targeted for 2023 2022 Daré Portfolio Accomplishments Include : Two Additional Portfolio Programs (DARE-GML and grant-funded DARE-...